Zacks: Brokerages Expect Avrobio Inc (AVRO) Will Announce Earnings of -$0.58 Per Share

Brokerages predict that Avrobio Inc (NASDAQ:AVRO) will announce earnings of ($0.58) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Avrobio’s earnings. The lowest EPS estimate is ($0.69) and the highest is ($0.41). The company is scheduled to report its next quarterly earnings results on Tuesday, February 12th.

On average, analysts expect that Avrobio will report full-year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($4.57) to ($1.82). For the next fiscal year, analysts forecast that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.93) to ($1.28). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Avrobio.

Avrobio (NASDAQ:AVRO) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.42.

Several equities research analysts have weighed in on AVRO shares. Zacks Investment Research upgraded shares of Avrobio from a “sell” rating to a “hold” rating in a report on Tuesday, October 16th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price (down from $47.00) on shares of Avrobio in a report on Tuesday, October 2nd. Guggenheim started coverage on shares of Avrobio in a report on Tuesday, October 9th. They issued a “buy” rating on the stock. Leerink Swann started coverage on shares of Avrobio in a report on Tuesday, November 27th. They issued a “market perform” rating on the stock. Finally, ValuEngine lowered shares of Avrobio from a “buy” rating to a “hold” rating in a report on Wednesday, October 24th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $39.50.

Institutional investors and hedge funds have recently bought and sold shares of the business. American International Group Inc. acquired a new stake in shares of Avrobio during the third quarter worth $210,000. Rhumbline Advisers acquired a new stake in shares of Avrobio during the third quarter worth $235,000. Man Group plc acquired a new stake in shares of Avrobio during the third quarter worth $329,000. TD Asset Management Inc. acquired a new stake in shares of Avrobio during the second quarter worth $217,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Avrobio during the third quarter worth $410,000. Institutional investors own 67.57% of the company’s stock.

NASDAQ AVRO traded up $1.10 during trading hours on Friday, hitting $26.79. The company’s stock had a trading volume of 80,748 shares, compared to its average volume of 59,340. Avrobio has a twelve month low of $20.30 and a twelve month high of $53.70.

About Avrobio

AVROBIO, Inc, a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease.

Featured Article: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Avrobio (AVRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avrobio (NASDAQ:AVRO)

Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit